Allergan PLC's pact with the Saint Regis Mohawk Tribe, intended to help Allergan secure patent protection for its dry eye blockbuster Restasis (cyclosporine), has done what many companies are hoping not to do – caught the attention of legislators in Washington, D.C.
Allergan's Tribe Deal Over Restasis Sparks Ire From Legislators
Pharmaceutical manufacturers have been hoping to fly under Washington, D.C.'s radar, but Allergan's attempt to shield Restasis from the IPR process using a controversial deal with a Native American tribe, has led to calls for an investigation.
